[Promoted to Ten Years of Courageous Action, Grateful and Striving to Write a New Chapter] Yao Xiaodong: Persisting in Excellence and Pursuing Outstanding Quality

Jiangxi Biological Products Research Institute Co., Ltd. is a pharmaceutical company in our district that pursues excellence in quality, insists on perfection, produces conscientious and reliable medicines, and has won market favor. When talking about the company's development history, one person must be mentioned. This person is Yao Xiaodong, the general manager of Jiangxi Biological Products Research Institute Co., Ltd. Now, let's "get up close" to understand his story with the company.

Jiangxi Biological Products Research Institute Co., Ltd. was founded in 1969, originally as the Jiangxi branch of the Shanghai Biological Products Research Institute under the Ministry of Health. It has a 50-year history in biopharmaceuticals. In 2002, it was restructured into a limited liability company with the approval of the Ji'an Municipal Government, and in September 2002, it relocated and transformed within our district. From a state-owned enterprise with a single product structure and annual sales of less than 1 million yuan, it has developed into a leading high-tech enterprise engaged in horse breeding, feeding, immune plasma collection, antitoxin research, production, processing, and sales. It has established a provincial enterprise technology center, Shenzhen R&D center, Hainan Pharmaceutical Research Institute, as well as immune horse plasma and pregnant mare serum technology R&D centers.

Talent is the driving force behind enterprise development. As a business manager, Yao Xiaodong clearly realizes that to grow and strengthen the company, it is necessary to continuously introduce and cultivate high-end technical talents and build its own research team. Yao Xiaodong said that to retain talent, on one hand, bold reforms and innovations are made in the enterprise management system and mechanisms; on the other hand, employee welfare and salary benefits are continuously improved, and relevant reward mechanisms are introduced. Meanwhile, over the years, the company has obtained multiple national patents in the field of antiserum through independent research and technological breakthroughs. Its products have represented China's antiserum manufacturing industry at the WHO antitoxin and immune serum seminar held in Geneva for display and exchange.

Insist on perfection, produce conscientious and reliable medicines. This is a phrase Yao Xiaodong often repeats. He requires that all production lines in the company must strictly follow GMP production regulations to ensure the quality of medicines is qualified and reliable. Over the years, Yao Xiaodong has firmly grasped the three main themes of research and development, production, and sales, dedicating himself to developing the company into a modern high-tech leading enterprise with an integrated "research-production-sales" line.

At the same time, the company focuses on its own growth and high-quality industrial transformation and upgrading, closely centering on the two strategic goals of "becoming a leader and listing on the main board." It taps internal potential, strengthens management, upgrades products, and connects the upstream and downstream industrial chains. The company has made significant progress, growing from annual sales of several million yuan in the past to nearly 300 million yuan now. To further optimize the product structure, the company has successively acquired two companies and a pharmaceutical research institute wholly. In 2019, it launched a project for technological transformation to upgrade the quality of existing varieties and improve product safety and effectiveness. The total investment of the project is 106 million yuan, planned to be completed and put into production by June 2021. After completion, the project will add 553 million yuan in sales revenue and nearly 100 million yuan in tax revenue.

"The company's growth and expansion are inseparable from the help and support of the development zone," said Yao Xiaodong. Over the years, with the care and support of the development zone, the company has focused on the two strategic goals of "becoming a leader and listing on the main board" for its own growth and high-quality industrial transformation and upgrading, tapping potential, strengthening management, enhancing technology, and connecting the industrial chain, achieving rapid development. It is understood that in recent years, our district, in line with the city's goal of building a trillion-level health industry, has formulated the "1+3" industrial support policies and development plans, increased guidance and assistance, promoted continuous improvement in enterprise R&D investment, advanced production process improvements in the industry, and continuously promoted industrial upgrading to achieve innovative development. At the same time, fully leveraging advantages such as convenient transportation, good ecology, rich resources, and profound heritage, a series of policies and services supporting the development of the biopharmaceutical industry have been formulated and implemented, creating a large number of well-known biopharmaceutical industries and quality products, and establishing a batch of famous and excellent brands.